Tag: GlobeNewswire

Authorization follows more than $59 million of recent capital raised, with planned programs funded through targeted 2027 milestones

CHARLOTTE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — via IBN — Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML; FSE: HK6), a Greenland-focused critical-minerals developer, today announced that its Board of Directors has authorized a $20 million share repurchase program as part of an updated capital allocation strategy focused on advancing its core mineral projects, maintaining strong liquidity, and maximizing long-term shareholder value.

Following the Company’s recent raising of more than $59 million in new capital, Greenland Mines believes it is well positioned to fund planned work at Sarfartoq and Skaergaard through targeted 2027 milestones while maintaining the financial flexibility to opportunistically repurchase shares. The Company will continue to prioritize drilling, technical studies, metallurgy, environmental programs and permitting, while evaluating strategic investments and partnerships supporting its North Atlantic Critical Metals Corridor strategy.

“Our recent financings have given Greenland Mines the balance sheet to aggressively advance our world-class Greenland assets while preserving meaningful strategic flexibility,” said Bo Møller Stensgaard, President of Greenland Mines. “Our priority remains disciplined investment in Sarfartoq and Skaergaard. At the same time, we believe our own shares may represent a compelling use of capital at certain valuations. This $20 million authorization gives us the ability to act when we believe repurchases can create attractive long-term value for our shareholders.”

Under the authorization, the Company may repurchase up to $20 million of its outstanding common stock from time to time through open-market transactions or other permissible methods, including pursuant to trading plans established under Rules 10b5-1 and 10b-18, where applicable. The timing and amount of any repurchases will depend on market conditions, the Company’s share price, liquidity requirements, project funding needs and other capital allocation considerations. The authorization does not obligate the Company to repurchase any particular amount of common stock and may be modified, suspended or discontinued at any time.

About Greenland Mines Ltd
Greenland Mines Ltd is listed on Nasdaq and develops mineral assets in Greenland, including the Skaergaard precious-metals project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. Its North Atlantic Critical Metals Corridor strategy seeks to connect Greenland resources with processing capacity and industrial customers in the United States and allied countries. The Company’s portfolio also includes a strategic investment in AnorTech, which is developing alumina and other materials from Greenland anorthosite.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “potential,” “could,” “may,” “will,” “should,” “estimate,” “objective” and similar expressions.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties. Many factors could cause actual results to differ materially, including exploration, resource-estimation, metallurgical, engineering, environmental, social, permitting, logistical, infrastructure, financing, commodity-price, market, counterparty and execution risks; the availability and level of participation of advisory board members; changes to planned programs and timelines; the Company’s ability to obtain required approvals and financing; and risks described in documents filed or to be filed with the U.S. Securities and Exchange Commission. No assurance can be given that studies, applications, partnerships, transactions, development decisions or production will occur on the timing contemplated or at all.

Readers should carefully consider these factors and the other risks and uncertainties described in the Company’s SEC filings. All information in this press release is provided as of its date, and the Company undertakes no obligation to update any forward-looking statement except as required by applicable law.

Investor Contact and Corporate Communications
ir@greenlandmines.com
www.greenlandmines.com

Corporate Communications
IBN
Austin, Texas
IBN.Ai | 512.354.7000 | Editor@IBN.Ai

Approval provides Rezolve Ai with capital allocation flexibility to advance towards planned repurchases while preserving capacity for growth, strategic M&A and other shareholder value initiatives

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — Rezolve Ai plc (NASDAQ: RZLV) (“Rezolve Ai” or the “Company”), a global leader in AI-powered commerce, today announced that it has received Court approval for the Company’s proposed capital reduction, an important step in enabling Rezolve Ai to implement its previously announced share repurchase program of up to $300 million.

The Court approval follows shareholder approval of the capital reduction and supports the Board’s objective of providing Rezolve Ai with greater flexibility to allocate capital in a manner that it believes best serves long-term shareholder value.

The Company expects to commence repurchases following the remaining procedural requirements necessary for the capital reduction to become effective having been completed, subject to market conditions, available capital, liquidity, capital allocation priorities, legal requirements and other relevant factors.

Under the Company’s proposed arrangements with BTIG, BTIG is expected to purchase ordinary shares in the market within agreed parameters, with Rezolve Ai repurchasing such shares from BTIG in accordance with applicable legal requirements and the terms of the program.

Daniel M. Wagner, Chairman and Chief Executive Officer of Rezolve Ai, said:
“Court approval of the capital reduction is an important milestone for Rezolve Ai and for our shareholders.

“We have consistently said that we believe the public market valuation of Rezolve Ai does not reflect the strength of our technology, the progress we have made commercially, or the scale of the opportunity ahead in AI-powered commerce.

“This approval gives us the flexibility to begin acting on that belief. Subject to completion of the remaining procedural steps and market conditions, we intend to commence repurchases where the Board believes doing so represents an attractive and disciplined use of capital.

“At the same time, we remain focused on growth. We continue to evaluate non-dilutive funding alternatives and strategic capital initiatives that could further enhance our flexibility over time, while preserving our ability to pursue strategic M&A, invest in the business and execute against our long-term plan.

“This is about confidence, discipline and shareholder value. We now have an important tool to act decisively and responsibly when we believe the market materially undervalues Rezolve Ai.”

The proposed repurchase program does not obligate the Company to acquire any specific number or dollar amount of shares, nor does it represent a commitment to deploy the full amount of the available capacity under the repurchase program. Any repurchases will be funded only from legally available funds and will remain subject to the Company’s liquidity position, capital allocation priorities, market conditions and applicable legal requirements. The program may be suspended, modified or discontinued at any time.

Further details regarding the capital reduction and share repurchase authority will be included in the Company’s public filings.

About Rezolve Ai
Rezolve Ai is a global leader in AI-powered commerce and engagement. Its technology helps retailers, brands, financial institutions and commerce platforms create intelligent, personalized customer experiences across search, discovery, engagement and transaction journeys.

Rezolve Ai’s platform is designed to connect consumers, merchants, banks and payment providers through intelligent commerce infrastructure that makes customer interactions more relevant, measurable and valuable. Through its AI-powered commerce capabilities and Reward’s financial engagement platform, Rezolve Ai is building the infrastructure for the next generation of personalized and agentic commerce.

Media Contact
Urmee Khan
Global Head of Communications
urmeekhan@rezolve.com
+44 7576 094 040

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the Company’s share repurchase program, the expected timing and implementation of any repurchases, the completion of remaining procedural requirements relating to the capital reduction, the Company’s capital allocation strategy, potential non-dilutive financing alternatives, strategic capital initiatives, potential M&A activity, market valuation, operating momentum, strategic position, growth prospects and long-term value creation.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, risks relating to the implementation of the proposed share repurchase program, completion of remaining procedural requirements relating to the capital reduction, market volatility, changes in trading liquidity, legal and regulatory restrictions, capital allocation requirements, business performance and other risks described in the Company’s filings with the Securities and Exchange Commission.

The share repurchase program does not require the Company to repurchase any specific number or dollar amount of shares and may be suspended, modified or discontinued at any time. Any repurchases will be made in compliance with applicable securities laws and other legal requirements.

Rezolve Ai undertakes no obligation to update any forward-looking statements, except as required by law.

The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona’s North American dealer network and giving more customers access to its products and technology.

CHARLOTTE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Dentsply Sirona (Nasdaq: XRAY), the world’s largest diversified manufacturer of professional dental products and technologies, today announced an expanded relationship with Midwest Dental Equipment & Supply, an independent, family-owned distributor of dental supplies, equipment, and technology.

Effective November 1, 2026, Midwest Dental will begin offering Dentsply Sirona’s technology portfolio in the United States, building on a relationship that has historically focused on consumables. The expanded relationship increases access to Dentsply Sirona’s digital dentistry solutions through Midwest Dental’s network of sales, service, and technical specialists.

The agreement reflects continued execution against Dentsply Sirona’s commitment to broaden access to its connected technology portfolio by expanding relationships with trusted distribution partners across North America.

Together, these agreements support Dentsply Sirona’s commercial strategy to increase customer access, strengthen coverage in key markets and support adoption of the Company’s connected technology solutions.

Founded in 1988 and headquartered in Wichita Falls, Texas, Midwest Dental Equipment & Supply is the largest independent, family-owned distributor in the Southern U.S. serving dental professionals nationwide, with sales, service, and technical teams on the ground in Texas, Oklahoma, New Mexico, and Arkansas.

“Midwest Dental has built strong relationships across the markets it serves, from independent practices to larger customer groups, making it an important partner as we continue expanding access to connected dentistry,” said Mark Bezjak, Group Vice President, Americas RCO at Dentsply Sirona. “By bringing our technology portfolio to Midwest Dental’s customers, we are extending the reach of a connected ecosystem designed to help practices improve efficiency, simplify workflows and support long-term growth.”

“Our customers trust us to help them make the best technology decisions that are right for their practice,” said Matt LeVasseur, Chief Executive Officer at Midwest Dental Equipment & Supply. “Adding Dentsply Sirona’s technology portfolio allows us to offer the industry’s leading and most complete digital dentistry solutions. When you add support from local service technicians, in-depth training and technical expertise, we’re able to exceed our customers’ expectations. In today’s busy marketplace, it is important for our customers to have an easy, seamless and profitable solution for same-visit crown restorations and Dentsply Sirona’s technology allows Midwest Dental to do that at the highest level”

The Midwest Dental agreement marks Dentsply Sirona’s seventh North American dealer partnership enhancement of 2026, following new technology agreements with Benco Dental Supply Co., The Burkhart Dental Supply Co., Nashville Dental, Inc., The Atlanta Dental Supply Company, and Medline Sinclair, as well as a renewed partnership with Patterson Dental. Together, these agreements support Dentsply Sirona’s commercial strategy to expand customer access, strengthen coverage in key markets and accelerate adoption of the Company’s connected technology solutions.

About Dentsply Sirona

Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information Investors:

Wade Moody
Senior Manager, Investor Relations
Investorrelations@dentsplysirona.com

Contact Information Press:

Marion Par-Weixlberger
Vice President, Public Relations, Corporate Communications & Brand
Publicrelations@dentsplysirona.com 

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. 
 
“We are excited to welcome BioLife team members to Repligen,” said Olivier Loeillot, President and Chief Executive Officer of Repligen. “BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies. Over the past several months, our teams have worked closely together to develop a thoughtful integration plan, and we are even more excited about the strategic rationale of bringing our organizations together and the value we will create for patients, customers, and shareholders.”
 
BioLife’s products are deeply embedded in the cell therapy workflow and highly complementary to Repligen’s existing offering in this market. BioLife’s differentiated biopreservation media portfolio, led by CryoStor^®, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. As a combined commercial team, BioLife will benefit from Repligen’s broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships.
 
In connection with the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash in lieu of any fractional shares of Repligen common stock.
 
Repligen intends to provide additional detail regarding the transaction’s expected impact on Repligen’s 2026 financial outlook in the upcoming third quarter 2026 earnings call.
 
Advisors
Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors and Goodwin Procter LLP served as legal counsel to Repligen. Centerview Partners, LLC served as financial advisor and K&L Gates LLP served as legal counsel to BioLife.
 
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
 
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements regarding the expected benefits of the transaction and Repligen’s ability to recognize such benefits; the anticipated financial impact of the transaction on Repligen; expectations for Repligen’s performance following the transaction; and beliefs and expectations about the cell therapy industry, including its growth, and BioLife’s position as a highly-differentiated cell processing tool leader. Words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and variations of such words and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
 
Repligen Contact: 
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com

PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio’s drug discovery models

MENLO PARK, Calif. and PARIS, Oct. 06, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and TychoBio, an AI drug discovery company, today announced a collaboration to generate full-length RNA data that TychoBio will use to train models for RNA therapy design. Under the terms of the agreement, TychoBio plans to use PacBio HiFi sequencing and Kinnex long-read RNA sequencing to generate data from more than 10,000 samples, building large-scale datasets linking the design of steric blocking antisense oligonucleotides (SBOs) to their effects across the transcriptome, with plans to expand the approach to siRNA and other RNA-targeting compounds.

TychoBio will test candidate RNA therapies and use PacBio sequencing to measure how each one changes the transcriptome across multiple cell types. Those results will become training data for models designed to predict which compounds are most likely to work, how long their effects may last, and where unintended effects may occur.

Training models for maximizing on-target efficacy and effect duration of SBOs requires an in-depth understanding of the interaction between SBOs and the cell’s transcriptome. By more fully characterizing the effect of SBOs in various cell lineages, TychoBio will unlock new insights into RNA regulation and SBOs mechanism of action, accelerating the development of safer and more efficient therapeutic designs.

“AI models are only as good as the data they are trained on. To effectively identify new rare disease treatments, we needed the highest quality biological data, which can only be generated using PacBio HiFi sequencing technology,” said Felix Raimundo, founder and CEO of TychoBio. “HiFi long read sequencing lets us see across full-length transcripts, including changes in isoforms and splicing of how the transcriptome is affected in rare diseases and which treatments could modify disease processes.” 

PacBio has partnered across the rare disease community to support the characterization, diagnosis and development of therapeutics to address the global burden of rare disease including through its global HiFiSolves Consortium, the n-Lorem Foundation and EspeRare, the GREGoR Consortium, Care4Rare Canada Consortium, the Genetic Alliance, Genomics England, and many academic collaborations. The company’s Kinnex products, alongside HiFi sequencing, enable screening of thousands of sequences in multiple cell lineages as well as the development of models of both efficacy and toxicity, which are critical to advance potential rare disease therapies out of the laboratory and into patient clinical trials.  

“Our work with TychoBio, like our collaboration with Basecamp Research, highlights the critical value that high-quality sequencing data plays in generating the foundational data that will power biological modeling in the AI ecosystem,” said Mark Van Oene, President and Chief Executive Officer of PacBio. “We believe that this critical work will enable the development of transformative therapies that ultimately improve the lives of patients with rare diseases and their families.” 

The collaboration puts HiFi data directly into the research workflow for designing RNA therapeutics for rare diseases.  

About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.  

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.  

About TychoBio
TychoBio is a frontier biology company that designs RNA therapeutics. Our data-generation platform unlocks scaling laws for gene therapies. We are bringing in therapeutic abundance to previously ignored patient populations. For more information, please visit www.tychobio.ai and follow @tychobio_ai.

Forward-Looking Statements 
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the availability, uses, accuracy, advantages, quality or performance of, or benefits of using, or expected benefits of using, PacBio products or technologies, including in connection with the collaboration between PacBio and TychoBio; plans related to potential therapy development and design, acceleration of safer and more efficient therapeutic designs and development, dataset generation, types of data generated, sequencing at least 10,000 samples, expansion to other compounds, and impact on rare disease characterization and diagnosis; transforming long-read sequencing data into meaningful genomic insights; value of high-quality sequencing data in AI ecosystem biological modeling; HiFi data being directly in the workflow for RNA therapy design for rare diseases; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in using new technologies; potential product performance and quality issues; rapidly changing technologies and extensive competition in, and potential FDA regulatory issues relating to, genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio’s patents or proprietary rights, among others. Additional factors that could materially affect actual results can be found in PacBio’s most recent filings with the Securities and Exchange Commission, including PacBio’s most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts:

Investors: 
ir@pacb.com

Media: 
pr@pacb.com

Roth Capital’s recent Buy initiation adds to the Anticipation Surrounding Expected October FDA discussion and NeOnc’s scheduled November 17 meeting

DENVER, Oct. 06, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — A fall calendar is bringing NeOnc Technologies Holdings’ (NASDAQ: NTHI) investigational brain-cancer programs into focus.

Anticipation is building as Roth Capital’s recent Buy initiation adds another Wall Street voice to the NTHI story. With Roth anticipating an October FDA discussion for NEO100 and NeOnc’s November 17 meeting for NEO212 on the calendar, the coming weeks put the company’s clinical development plans firmly in the spotlight.

For traders following biotech milestones, NTHI offers a timely story to research: clinical findings, regulatory discussions and the potential next steps for two brain-cancer therapies.

October: Attention turns to NEO100

Jonathan Aschoff’s research indicate that he anticipates an FDA Type B end-of-Phase 2 meeting for NEO100 in October. The Roth Capital analyst also sees pivotal trials potentially beginning before year-end.

The anticipated discussion could help clarify the program’s next clinical steps, including the evidence and study design needed to advance development. For investors following NeOnc, that makes regulatory feedback a central part of the fall watchlist.

November 17: NEO212 takes its turn

NeOnc has announced an in-person FDA End-of-Phase 1 Type B meeting for NEO212 on November 17, 2026, about six weeks away.

The company plans to discuss its proposed patient population, trial design, endpoints, dose selection and evidence needed to support a future marketing application.

Together, the anticipated NEO100 discussion and scheduled NEO212 meeting create two opportunities for greater clarity on NeOnc’s development strategy this fall.

Brain-cancer research gives the calendar substance

In August, NeOnc reported that its NEO100 Phase 2a study met its primary endpoint. The company reported six-month progression-free survival of 48.9%, compared with a prespecified historical benchmark of 20%, and median overall survival of 26.09 months.

The results came from an open-label, 24-patient study of patients with recurrent or progressive IDH1-mutant high-grade glioma. The findings now form part of the evidence supporting the company’s pursuit of further clinical development.

NEO100 is administered intranasally and is designed to address drug-delivery challenges associated with treating cancers in the brain. Alongside it, NeOnc is advancing NEO212, an investigational oral therapy.

Orphan Drug, Fast Track and Rare Pediatric Disease designations

NeOnc reports that NEO100 holds FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations.

These designations add to the program’s regulatory background as NeOnc works toward its next development milestones. The upcoming discussions could help define how the company builds on its clinical findings and advances its investigational therapies.

Wall Street’s coverage has expanded

Roth Capital’s September 24 Buy initiation followed earlier Buy initiations from Alliance Global Partners, Maxim Group and BTIG.

That expanding coverage gives investors several analyst perspectives on NeOnc’s programs, development strategy and commercial potential. Roth’s recent initiation adds a fresh assessment as the company enters its fall regulatory window.

The catalyst window is here

For traders building a biotech watchlist, NTHI brings together several developments’ worth following: two investigational therapies, reported clinical progress, multiple Buy initiations and regulatory discussions approaching in October and November.

The next chapter will unfold through FDA feedback, company updates and subsequent clinical plans. With November 17 just over six weeks away and Roth anticipating a separate discussion this month, NeOnc has a calendar investors can follow closely.

For further details, please click here for full NTHI report and here for full NTHI compensation disclosure and third-party-content policies.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

Almere, the Netherlands
October 6, 2026

ASM International N.V. (Euronext Amsterdam: ASM) will report its third quarter 2026 financial results at approximately 6:00 p.m. CET on Tuesday, October 27, 2026.

ASM will host the quarterly earnings conference call and webcast on Wednesday, October 28, 2026, at 3:00 p.m. CET.

Conference-call participants should pre-register using this link to receive the dial-in numbers, passcode and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible at this link.

About ASM

ASM International N.V., headquartered in Almere, the Netherlands, and its subsidiaries design and manufacture equipment and process solutions to produce semiconductor devices for wafer processing, and have facilities in the United States, Europe, and Asia. ASM’s common stock trades on the Euronext Amsterdam Stock Exchange (symbol: ASM). For more information, visit ASM’s website at www.asm.com.

Contacts
Investor and media relations	Investor relations
Victor Bareño	Daniel Uribe
T: +31 88 100 8500	T: +31 88 100 8127
E: investor.relations@asm.com	E: investor.relations@asm.com

KALMAR CORPORATION, TRADE PRESS RELEASE, 6 OCTOBER 2026 AT 16:00 (EEST)

Kalmar announces proactive safety update for Ottawa T2 terminal tractors

On 5 October 2026, Kalmar issued a recall notice with the US National Highway Traffic Safety Administration (NHTSA). The recall applies to the Ottawa T2 4×2 DOT/EPA, Ottawa T2 Off Road, and Ottawa T2 6×4 DOT/EPA terminal tractor configurations. 

The power distribution board in the cabin can experience a breakdown of electrical insulation resistance and may also be subject to a short circuit and has, in very rare circumstances, led to thermal events. Units involved with these events account for a very small portion of the Ottawa T2 fleet—less than 0.001% of total units.  

While these instances are rare, Kalmar is taking proactive steps to address the issue and support the continued safety and reliability of the Ottawa T2 units. The recall will provide the addition of a remote ground stud (RGS/fuse) to completely isolate certain electrical circuits and prevent thermal events from occurring. 

Kalmar will notify customers directly in the upcoming weeks with further details on implementation of the RGS in the affected vehicles. The Kalmar service team will work directly with customers to coordinate scheduling, helping return their vehicles to service as promptly as possible.   

“Customer safety and the reliability of their operations are of utmost importance to us,” said Thor Brenden, President, Terminal Tractors, Kalmar. “We are taking direct action to reach affected owners, provide clear guidance and complete the necessary work. We will work closely with customers and our service network throughout this process to help keep their Ottawa T2 terminal tractor fleets productive.”

Further information for the press:
Cristina Murray, Director, Marketing & Communications
cristina.murray@kalmarglobal.com

Kalmar (Nasdaq Helsinki: KALMAR) is moving goods in critical supply chains around the world, with the vision to be the forerunner in sustainable material handling equipment and services. The company offers a wide range of industry shaping heavy material handling equipment and services to ports and terminals, distribution centres, manufacturing and heavy logistics. Headquartered in Helsinki, Finland, Kalmar operates globally in over 120 countries and employs approximately 5,300 people. In 2025, the company’s sales totalled approximately EUR 1.7 billion. www.kalmarglobal.com  

NORTHFIELD, Ill., Oct. 06, 2026 (GLOBE NEWSWIRE) — Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report third quarter 2026 financial results on Wednesday, November 4, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results.

Information about Medline’s financial results, including a link to the live webcast, will be available on the Events page of Medline’s Investor Relations website at ir.medline.com. A replay of the webcast will be available following the event through the same website.

About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries. To learn more about how Medline makes healthcare run better, visit www.medline.com.

Contacts
Investor Relations:
Karen King
Global Head of Investor Relations

Patrick Flaherty
Director, Investor Relations

(847) 247-7222
IR@medline.com

Media Relations:
Ben Fox
Vice President, Corporate Communications
(224) 327-9999
MedlineMediaRelations@medline.com

Source: Medline Inc.

• Duluth Trading best-selling products help shoppers find useful gifts for everyone on their list 
• Top rated gifts include underwear, durable workwear, gardening gear, outdoor apparel and practical gifts under $50
• Holiday gift shopping can be done at DuluthTrading.com and at its 60+ retail stores nationwide

MOUNT HOREB, Wis., Oct. 06, 2026 (GLOBE NEWSWIRE) — With the holiday shopping season ramping up, Duluth Trading Co. (Duluth), a leading brand in functional workwear and outdoor apparel, releases its top gift ideas for early shoppers based on customer reviews and ratings. With Buck Naked^® underwear that won’t ride up, Fire Hose^® work pants built for real work, the Heirloom Gardening® collection’s blend of functionality and favorite patterns, and the tuck-and-stay Longtail T^®, Duluth has become the go-to for hard-to-shop-for people and gifts that actually get used.

The proof is in the reviews: Best-selling holiday gifts
Duluth’s top gift ideas for early shoppers include favorite products with thousands of positive ratings and repeat purchases. The products are bestsellers for good reason: they solve everyday annoyances, and as gifts, they offer more than a festive holiday print. That’s what makes these thoughtful, useful gift picks for every practical person, outdoorsman, gardener, DIYer, and the one who “doesn’t want anything” on your holiday shopping list.

• Buck Naked^® underwear: the gift for anyone tired of underwear that rides up. One of Duluth Trading’s most-reviewed and most-gifted products, the quick-drying Men’s Buck Naked underwear has earned more than 30,000 five-star reviews, with the Performance Boxer Briefs rated roughly 4.8 out of 5 across more than 17,000 reviews. With no-ride-up and no-chafing, it’s the everyday essential people replace the least and complain about the most; the rare practical gift that earns a real “how did I not have this already.” Buck Naked underwear is available for men and women in gift-friendly multipacks and collectible prints.
• Fire Hose^® Work Pants: the gift for people who work with their hands. Rugged canvas with a Crouch Gusset™, an extra panel of fabric in the crotch for more room where it counts when kneeling or bending. For a mechanic, contractor, woodworker, or weekend warrior, Fire Hose is the gift they’ll wear until it wears out.
• Heirloom Gardening^® Bib Overalls: the gift for the four-season gardener. Beloved by vegetable gardeners, flower gardeners, homesteaders, landscapers and anyone who would rather spend Saturday in the garden than on the couch. Duluth debuted its best-selling Heirloom® Gardening Bib Overalls a decade ago, and gardeners quickly fell for the material, features and seasonal prints. The signature DuluthFlex^® ripstop construction offers a super-strong stretch and brush-clean finish, earning a 4.7-star rating from more than 3,800 online reviews.
• The Longtail T^® Shirt: the gift for anyone whose shirt won’t stay tucked. Cut three inches longer in the back, so it stays put no matter how much the wearer bends or reaches. The original problem-solver that launched Duluth’s apparel line. It’s an easy, universally appreciated gift across sizes and budgets.
• Tool organizers, garden accessories, and work bags: for the person always hunting for a tool. Duluth got its start in 1989 by inventing a new category of tool organizer, turning an ordinary bucket into a mobile workbench. This design aspect runs through today’s pocket-loaded bags, totes and organizers, creating ideal gifts for anyone who likes their gear close at hand and their workspace under control, whether in the garage or in the garden.

Duluth Trading gifts for the entire shopping list

• Best gifts for practical people: Duluth specializes in functional apparel, accessories and gear designed to solve real-world problems.
• Best gifts for gardeners: The Heirloom Gardening^® collection includes durable apparel and accessories designed for working outdoors.
• Best gifts for DIYers: Workwear, aprons, bags, tools and accessories are made for people who like to build, fix, tinker and get things done.
• Best gifts for men: Popular choices include Buck Naked^® underwear, Armachillo® cooling apparel, Fire Hose® work pants and everyday layers.
• Best gifts for women: Gift options range from gardening and workwear to comfortable everyday apparel and weather-ready layers.
• Best gifts under $50: Shoppers can find underwear, socks, accessories, apparel and useful gear at accessible price points.
• Best stocking stuffers: Small, useful gifts include underwear, socks, hats, gloves and everyday accessories.
• Best gifts for someone who has everything: Look for Duluth’s problem-solving products: the things they may not know they need until they have them.

Holiday Shopping FAQs

What are the best gifts from Duluth Trading?
Some of Duluth’s most giftable products include Buck Naked^® underwear, Fire Hose^® workwear, Heirloom Gardening^® apparel and gear, Armachillo^® cooling apparel, socks, accessories, and other functional everyday essentials. The best choice depends on the recipient’s interests, lifestyle and budget.

What are good Duluth Trading gifts for men?
Popular men’s gifts include Buck Naked^® underwear, Armachillo^® cooling apparel, Fire Hose^® work pants, shirts, socks and other everyday apparel and accessories. Duluth’s men’s gift assortment includes options for DIYers, outdoor enthusiasts, workers and men who value comfort and function.

What are good Duluth Trading gifts for women?
Duluth offers gifts for women across gardening, workwear, outdoor apparel and lifestyle clothing. Popular categories include Heirloom Gardening^®, No-Yank^® apparel, Armachillo^® cooling styles and functional everyday essentials.

What are good gifts for gardeners?
Good gifts for gardeners include durable gardening apparel, women’s bib overalls, garden pants, gloves, totes, sun protection and other gear designed for working outdoors. Duluth’s Heirloom Gardening^® collection for women is specifically designed with gardeners in mind.

What are good gifts for DIYers?
Practical gifts for DIYers include durable work pants, shirts, aprons, tool bags, organizers and other gear designed for people who build, repair, craft and work with their hands.

What are good stocking stuffers from Duluth Trading?
Duluth Trading stocking stuffers include underwear, socks, hats, gloves and other small accessories and everyday essentials.

Does Duluth Trading have gifts under $50?
Yes. Duluth Trading offers a selection of gifts under $50, including underwear, socks, accessories, apparel and smaller tools and gear.

What should I buy for someone who has everything?
Consider a practical, problem-solving gift they may not already own. Duluth Trading specializes in functional apparel, accessories and gear designed around everyday needs, making its products a useful option for hard-to-shop-for recipients.

Where can I buy Duluth Trading holiday gifts?
Customers can enjoy a one-stop shopping experience for holiday gifts at DuluthTrading.com, at more than 60 Duluth Trading retail stores nationwide or shop a curated collection of Duluth’s most popular items on Amazon. Find a Duluth Trading retail store near you: duluthtrading.com/find-stores/.

Media Contact
TURNER
duluth@turnerpr.com